FDA Approves Two Cell-Based SCD Gene Therapies
February 2024The U.S. Food and Drug Administration (FDA) approved exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) for the treatment of sickle cell disease (SCD) in patient
Updated on: February 18,2024
6
FDA Approves Two Cell-Based SCD Gene Therapies
February 2024The U.S. Food and Drug Administration (FDA) approved exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) for the treatment of sickle cell disease (SCD) in patient
Updated on:February 18,2024
6
